NASDAQ · CTCXW
Carmell Therapeutics Corporation
Healthcare · Biotechnology
$0.03
Down-$0.02 (-45.40%)
Updated Aug 14, 2026, 2:44 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 558.17K
- P/E ratio
- -0.13
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 29.79K
- Avg. volume
- 18.53K
Price performance
CTCXW price history
1M range · 0 trading sessions · Daily adjusted prices
CTCXW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CTCXW news
The latest Smart Investors Daily articles mentioning CTCXW.
Stock researchCompany · Overview
CTCXW research
Overview
Company profile and research snapshot.
Company profile
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
